Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 5, 2001, Pages 1281-1289

  Blackstock, A William ^a,b   Lesser, Glenn J ^a   Fletcher Steede, June ^a   Case, L Douglas ^a   Tucker, Robert W ^a   Russo, Suzanne M ^a   White, Douglas R ^a   Miller, Antonius ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiation; Sensitization; Thoracic

Indexed keywords

HISTOLOGY; RADIATION; TOXICITY; TUMORS;

THORACIC RADIATION;

ONCOLOGY;

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGITIS; FEMALE; HISTOLOGY; HUMAN; LEUKEMIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; THORAX;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; THORAX;

EID: 0035577889     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01732-1     Document Type: Article

References (64)

1. Cancer statistics, 1997
2. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma
3. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
4. Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer
5. Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer
6. Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer
7. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer
8. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer (NSCLC): Initial report of the Radiation Therapy Oncology Group (RTOG) 9410
9. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
10. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
11. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
12. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
13. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer
14. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
15. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
16. A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer
17. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
18. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results
19. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
20. Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer
21. A Phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
22. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer
23. Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study
24. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
25. 2) levels
26. A randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
27. Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule
28. Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study
29. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
30. Radiosensitization of human tumor cells by gemcitabine in vitro
31. Effects of gemcitabine in normal and transformed human lung cell cultures: Cytotoxicity and increase in radiation sensitivity
32. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
33. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
34. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
35. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model
36. Maximizing therapeutic gain with gemcitabine and fractionated radiation
37. Gemcitabine: In vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dosing schedule: Preclinical observations relevant to gemcitabine clinical trials
38. Enhancement of tumor radioresponse in vivo by gemcitabine
39. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines
40. Pilot trial of concurrent gemcitabine (GEM) and radiotherapy as a bladder preservation strategy
41. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
42. Phase I study of gemcitabine combined with radiotherapy with or without amifostine in patients with locally advanced head and neck cancer
43. A Phase I trial of radiation dose escalation with full dose gemcitabine (GEM) in patients (pts) with pancreatic cancer
44. Phase I study of gemcitabine (G) and escalating dose radiation therapy (RT) in patients with pancreatic cancer
45. Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC
46. Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus Cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC)
47. Phase I study of gemcitabine and radiotherapy in stage III non-small cell lung cancer
48. Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study
49. Gemzar (Gemcitabine) with thoracic radiotherapy: A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
50. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiation for unresectable stage III non-small cell lung cancer
51. A new international staging system for lung cancer
52. Workshop on phase I study design: Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996
53. Improving treatment planning accuracy through multimodality imaging
54. Reporting results of cancer treatment
55. Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin: A Phase I trial for patients with stage III non-small cell lung cancer (NSCLC)
56. The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
57. Schedule-dependent antitumor effect of gemcitabine in in vivo model system
58. Low-dose weekly 24-hour infusion gemcitabine (G) in metastatic and relapsed solid tumors
59. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
60. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer
61. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus
62. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)